EGFR and glioblastoma: Immunotherapies against EGFR have been constructed with varying goals in mind: use EGFR as an activation target; inhibit EGFR signaling via blocking ligand binding; and use combination EGFR-targeting tyrosine kinase inhibitor drugs alongside other GBM immunotherapy strategies such as immune checkpoint inhibitors and CAR T cells [89,93,96,97,98].